
Conference Coverage
about 1 month ago
NeuroOp Guru at AAO 2026: Blurry vision in MS isn’t always a relapseabout 1 month ago
AAO 2026: Rethinking dry eye as a spectrum of ocular painabout 1 month ago
AAO 2026: Preventing complications in uveitic cataract surgeryabout 1 month ago
AAO 2026: Setting realistic expectations with refractive IOLsabout 1 month ago
AAO 2026: Comprehensive ophthalmologists are the uveitis front lineabout 1 month ago
AAO 2026: The optic nerve is the barrier to sight in eye transplantTrending on the Eye Care Network
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
First patient dosed in EMERALD trial of EO2002 for corneal edema
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
MacuMira receives CE Mark for microcurrent treatment of dry AMD
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion
Latest News

Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada

ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy

First patient dosed in EMERALD trial of EO2002 for corneal edema

Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model

Axial length: a critical factor in primary rhegmatogenous retinal detachment

Shorts










Digital Edition



Podcasts
Continuing Medical Education
All News

The Neurolens N3 gains EU MDR certification for Contoured Prism lens prescribing, with first European launches planned for 2027.

The non-invasive device, already available in Canada, Australia, and New Zealand, delivers low-level microcurrent through closed eyelids in 32-minute in-clinic sessions.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

A structure-first approach to blepharoplasty and filler yields more durable, natural results.

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

Industry leadership gave her a wider lens that she now brings to patient care.

A systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Retinal thickness fell by more than 100 µm within 8 weeks in each case.

Two cases highlight when to start therapy in extensive and early atrophy

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

The once-daily combination drop is approved by the FDA to treat presbyopia.























